Krista Cline Net Worth

The estimated Net Worth of Krista Cline is at least $8.81 Thousand dollars as of 30 May 2019. Ms Cline owns over 21,900 units of Perspective Therapeutics Inc stock worth over $8,806 and over the last 5 years she sold ISR stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms Cline ISR stock SEC Form 4 insiders trading

Ms has made over 1 trades of the Perspective Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 21,900 units of ISR stock worth $5,694 on 30 May 2019.

The largest trade she's ever made was exercising 21,900 units of Perspective Therapeutics Inc stock on 30 May 2019 worth over $5,694. On average, Ms trades about 10,950 units every 0 days since 2019. As of 30 May 2019 she still owns at least 22,933 units of Perspective Therapeutics Inc stock.

You can see the complete history of Ms Cline stock trades at the bottom of the page.

Ms. Krista Cline biography

Krista Cline is the Sr. Director of Operations & Corp. Sec. at Perspective Therapeutics Inc.

How old is Ms Cline?

Ms Cline is 39, she's been the Sr. Director of Operations & Corp. Sec. of Perspective Therapeutics Inc since . There are 13 older and 3 younger executives at Perspective Therapeutics Inc. The oldest executive at Perspective Therapeutics Inc is Philip Vitale, 73, who is the Independent Director.

What's Ms Cline's mailing address?

Krista's mailing address filed with the SEC is 350 HILLS STREET, SUITE 106, , RICHLAND, WA, 99354.

Insiders trading at Perspective Therapeutics Inc

Over the last 18 years, insiders at Perspective Therapeutics Inc have traded over $0 worth of Perspective Therapeutics Inc stock and bought 1,651,741 units worth $855,397 . The most active insiders traders include Lori A Woods, Thomas C Lavoy, and Dwight William Babcock. On average, Perspective Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $14,501. The most recent stock trade was executed by Lori A Woods on 13 April 2023, trading 187,500 units of ISR stock currently worth $114,375.

What does Perspective Therapeutics Inc do?

Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.

Complete history of Ms Cline stock trades at Perspective Therapeutics Inc

Perspective Therapeutics Inc executives and stock owners

Perspective Therapeutics Inc executives and other stock owners filed with the SEC include:

• Lori Woods,
  Chief Executive Officer, Director
• Lori A. Holmes-Woods,
  CEO & Director
• Michael Krachon,
  Executive Vice President of Sales and Marketing
• William Cavanagh,
  Chief Research and Development Officer
• Michael L. Krachon,
  Exec. VP of Sales & Marketing
• Jennifer Streeter,
  COO & VP of HR
• William A. Cavanagh III,
  Chief R&D Officer
• Krista Cline,
  Senior Director of Operations, Corporate Secretary
• Philip Vitale,
  Independent Director
• Alan Hoffmann,
  Independent Director
• Jonathan Hunt,
  Chief Financial Officer, Co-Principal Financial Officer
• Mark Austin,
  Controller, Co-Principal Financial and Principal Accounting Officer
• Jennifer Streeter,
  Chief Operating Officer, Vice President of Human Resources
• Michael McCormick,
  Independent Chairman of the Board
• Krista Cline,
  Sr. Director of Operations & Corp. Sec.
• Mark J. Austin CPA,
  VP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec.
• Jonathan R. Hunt,
  CFO & Co-Principal Financial Officer
• Frank Morich,
  Director
• Brien Ragle,
  Controller
• Dwight William Babcock,
  CEO
• Matthew Branson,
  Principal Fin & Acct Officer
• Robert F Iii Williamson,
  Director
• Thomas C Lavoy,
  Director
• Albert Louis Smith,
  Director
• Roger Girard,
  CEO/President
• Robert R Kauffman,
  Director
• Fredric Swindler,
  Vice President
• David Swanberg,
  EVP Operations & Secretary
• Stephen Boatwright,
  Director